Patent ID: 6566367
Filing Date: 2003-05-20
Classification: A61P,C07D

Abstract:
A compound of Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein:X is oxygen or H2; A, D, V, W, Y and Z are independently N or CR1; B is CR2; E is CR3; R1 is independently selected at each occurrence from: (i) hydrogen, halogen, hydroxy, amino, nitro, cyano, â€”C(&boxH;O)NH2 and â€”COOH; and (ii) L-RA-Q-G, wherein: L is a bond, â€”Oâ€”, â€”C(&boxH;O)â€”, â€”OC(&boxH;O)â€”, â€”C(&boxH;O)Oâ€”, â€”Oâ€”C(&boxH;O)Oâ€”, â€”S(O)nâ€”, â€”NRBâ€”, â€”C(&boxH;O)NHRBâ€”, â€”NHRBC(&boxH;O)â€”, â€”NRBS(O)nâ€” or â€”S(O)nNRBâ€”; n is independently chosen at each occurrence from 0, 1 or 2; RA is (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl, (C3-C8)cycloalkynyl, quinazoline, pyridine, oxazole, pyrazine, piperazinyl, pyrimidinyl, morpholinyl each of which is optionally substituted with from 1 to 5 substituents independently selected from hydroxy, halogen, amino, cyano, nitro, (C1-C6)alkyl and halo(C1-C6)alkyl; Q is a bond, â€”Oâ€”, â€”C(&boxH;O)â€”, â€”OC(&boxH;O)â€”, â€”C(&boxH;O)Oâ€”, â€”Oâ€”C(&boxH;O)Oâ€”, â€”S(O)nâ€”, â€”CHRBâ€”, â€”NRBâ€”, â€”C(&boxH;O)NHRBâ€”, â€”NHRBC(&boxH;O)â€”, â€”NRBS(O)nâ€” or â€”S(O)nNRBâ€”; RB is independently selected at each occurrence from hydrogen, (C1-C8)alkyl, (C3-C8)cyclOalkyl, (C3-C8)cycloalkyl(C1-C8)alkyl and (C1-C8)alkyl(C3-C8)cycloalkyl; and G is: hydrogen; or (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C8)cycloalkyl(C1-C8)alkyl, or a 3- to 10-membered carbocyclic, quinazoline, pyridine, oxazole, pyrazine, piperazinyl, pyrimidinyl, morpholinyl, each of which is optionally substituted with from 1 to 5 substituents independently selected from hydroxy, halogen, amino, cyano, nitro, (C1-C8)alkyl, halo(C1-C8)alkyl, (C1-C8)alkoxy, â€”NH(C1-C8)alkyl, â€”N((C1-C8)alkyl)2, NHC(&boxH;O)(C1-C8)alkyl, â€”N(C1-C8)alkylC(&boxH;O)(alkyl), â€”NHS(O)s(C1-C8)alkyl, S(O)s(C1-C8)alkyl, â€”S(O)sNH(C1-C8)alkyl and â€”S(O)sN((C1-C8)alkyl)2, wherein s is 0, 1 or 2; R2 and R3 are independently selected at each occurrence from: (i) hydrogen, halogen, hydroxy, amino, nitro, cyano, â€”C(&boxH;O)NH2 and â€”COOH; and (ii) T-RC-U-M, wherein: T is a bond, â€”Oâ€”, â€”C(&boxH;O)â€”, â€”OC(&boxH;O)â€”, â€”C(&boxH;O)Oâ€”, â€”Oâ€”C(&boxH;O)Oâ€”, â€”S(O)nâ€”, â€”NRDâ€”, â€”C(O)NHRDâ€”, â€”NHRDC(&boxH;O)â€”, â€”NRDS(O)nâ€” or â€”S(O)nNRDâ€”; n is independently chosen at each occurrence from 0, 1 or 2; RC is (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl or a 3- to 10-membered carbo cyclic, quinazoline, pyridine, oxazole, pyrazine, piperazinyl, pyrimidinyl, morpholinyl, each of which is optionally substituted with from 1 to 5 substituents independently selected from hydroxy, halogen, amino, cyano, nitro, (C1-C6)alkyl and halo(C1-C6)alkyl; U is a bond, â€”Oâ€”, â€”C(&boxH;O)â€”, â€”OC(&boxH;O)â€”, â€”C(&boxH;O)Oâ€”, â€”Oâ€”C(&boxH;O)Oâ€”, â€”S(O)nâ€”, â€”CHRDâ€”, â€”NRDâ€”, â€”C(&boxH;O)NHRDâ€”, â€”NHRDC(&boxH;O)â€”, â€”NRDS(O)nâ€” or â€”S(O)nNRDâ€”; RD is independently selected at each occurrence from hydrogen, (C1-C8)alkyl, (C3-C8)cycloalkyl, (C3-C8)cycloalkyl(C1-C8)alkyl and (C1-C8)alkyl(C3-C8)cycloalkyl; and M is: hydrogen; or (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8) alkynyl or a 3- to 10-membered carbocyclic, quinazoline, pyridine, oxazole, pyrazine, piperazinyl, pyrimidinyl, morpholinyl, each of which is optionally substituted with from 1 to 5 substituents independently selected from hydroxy, halogen, amino, cyano, nitro, (C1-C8) alkyl, halo(C1-C8)alkyl, (C1-C8)alkoxy, â€”NH(C1-C8)alkyl, â€”N((C1-C8)alkyl)2, NHC(&boxH;O)(C1-C8)alkyl, â€”N(C1-C8)alkyl C(&boxH;O)(alkyl), â€”NHS(O)s(C1-C8)alkyl, â€”S(O)s(C1-C8)alkkyl, â€”S(O)sNH(1-C8)alkyl and â€”S(O)sN((C1-C8)alkyl)2, wherein s is 0, 1 or 2.